Summary
- Temple acquires Longevous, a London longevity practice, as Goyal’s wearable startup pushes toward its first product launch.
- Longevous founders Dr. Robert Mohr and Dr. Avi Roy join Temple full-time, as CMO and Head of Science.
- The deal comes months after Temple raised a friends-and-family round at a roughly $190 million valuation.
Deepinder Goyal’s health-tech startup has just made its first acquisition, and it isn’t a hardware company. Temple acquires Longevous, a London-based longevity medicine practice, in a move that says more about credibility than technology.
Goyal announced the deal on X on Thursday. Longevous founders Dr. Robert Mohr and Dr. Avi Roy will join Temple full time, while the London practice continues operating under its existing model and keeps serving its current clients. Financial terms weren’t disclosed.
For a startup that’s spent the better part of a year fielding questions about its science, this is a pointed answer.
Who’s joining, and why it matters
Mohr will join as Temple’s chief medical officer, bringing nearly two decades of clinical experience, having moved from emergency medicine into evidence-based longevity medicine. Roy, an Oxford-trained biomedical scientist, becomes Head of Science; he previously co-founded Founders Health and UDA, and was a research fellow at Oxford’s Centre for the Advancement of Sustainable Medical Innovation.
This isn’t a cold acquisition either. Goyal has said his association with Mohr and Roy began after meeting them at a dinner in London, after which the two tested Temple’s technology over a two-month period and got involved in validating its data.
That detail matters more than it looks. Temple’s core product is an experimental wearable, worn near the temple, that claims to track signals linked to cerebral blood flow, oxygenation, and heart rate, along with responses to exercise, sleep, recovery, and meditation. Bringing in outside doctors who spent months stress-testing that data, rather than simply hiring a medical advisor, reads like Temple wanted its harshest available critics inside the tent first.
Read More: What Is Temple Wearable? Deepinder Goyal’s New AI Health Ring
The credibility problem this is meant to fix
Temple has never been short on attention. It raised a friends-and-family round earlier this year from Zomato-adjacent backers and marquee investors, at a roughly $190 million valuation. What it’s been short on is independent validation. Neurologists quoted in earlier reports have questioned whether measurements taken from one point on the head can accurately represent blood flow throughout the brain, and experts have stressed that a consumer wearable shouldn’t substitute for established medical tests unless its claims are properly validated.
That’s the gap Longevous is meant to close. The acquisition marks a structural pivot for Temple, moving it from speculative hardware engineering toward institutional clinical validation ahead of its debut product launch. It also gives Temple an integrated clinical practice, one that can potentially convert wearable users into higher-margin concierge medical clients down the line.
Read More : Deepinder Goyal Temple Wearable: Brain Health Device 2025
What’s next
Temple is preparing to launch its first product, with limited pre-orders expected soon and shipments planned before the end of 2026. Longevous, founded in 2025 and focused on preventive and precision medicine, keeps its London client base intact while doubling as the scientific backbone for Temple’s next phase.
Why founders should be watching this
Set aside the wearable itself for a second. The interesting move here is the playbook: buy scientific legitimacy instead of building it slowly in-house.
For Indian founders building in healthtech, deeptech, or any hardware category where trust is the real bottleneck, that’s a pattern worth noting. Regulatory and scientific credibility is usually the slowest thing to build organically, especially for a startup making health claims. Acquiring a small, credible clinical team, rather than hiring individual advisors, compresses that timeline and gives a product story it can point to before a single unit ships.
It’s also a reminder that acquisitions aren’t just for scale anymore. Founders are increasingly using them to buy trust, talent, and validation at an early stage, not just revenue or market share.
Temple’s wearable still has to prove itself once it’s in consumers’ hands. But with Mohr and Roy now inside the company, Goyal has bought himself two people whose job is to make sure the science holds up before that happens.
FAQs
What does Temple’s acquisition of Longevous involve?
Temple, Deepinder Goyal’s wearable startup, has acquired London-based longevity medicine practice Longevous for an undisclosed sum. Longevous continues serving its existing clients while its founders join Temple full-time.
Who are Dr. Robert Mohr and Dr. Avi Roy?
Mohr is a board-certified physician with nearly two decades of clinical experience who moved into longevity medicine; he joins as Temple’s Chief Medical Officer. Roy is an Oxford-trained biomedical scientist joining as Head of Science.
Why did Temple acquire a longevity medicine practice?
Temple’s wearable has faced questions over its unvalidated health claims. Acquiring Longevous brings in clinical and scientific expertise to help validate the product ahead of its launch.
When will Temple’s wearable launch?
Temple is preparing limited pre-orders soon, with shipments planned before the end of 2026.
How much was Temple valued at in its last funding round?
Temple raised a friends-and-family round earlier in 2026 at a post-money valuation of roughly $190 million, led by Goyal with participation from Steadview Capital and other investors.
Will Longevous continue operating independently?
Yes. Longevous keeps its existing client base and operating model in London, now functioning as part of Temple rather than being folded into it entirely.
